Clinical and Experimental Ophthalmology · 2004 · 59 citations · 26 references
MedicineOphthalmologyPediatricsPediatric OptometryPediatric TherapeuticsStrabismusAtropine TherapyCycloplegic AgentsCycloplegic RefractionPediatric Clinical TrialsPediatric PharmacologyPediatric StrabismusAtropine CycloplegiaCyclopentolate CycloplegiaCycloplegic Refraction In ChildrenDrug Safety In CycloplegiaDrug Safety In InfantsPediatric Cycloplegic UseSpherical Equivalent RefractionTropicamide Cycloplegia
BACKGROUND: The ideal cycloplegic drug that is safe, effective and convenient in children is not yet available. This study aimed to evaluate the safety and efficacy of three cycloplegic regimens in hyperopic children with pigmented irides. The responses to cycloplegia in different age groups and presence of strabismus were also compared. METHODS: Tropicamide 0.5% and phenylephrine 0.5% (regimen I), tropicamide 1.0% and cyclopentolate 1.0% (regimen II), and atropine 1.0% (regimen III) were evaluated in 25 children using a crossover study design. Cycloplegic refractions were assessed. RESULTS: The mean age of the children was 5.7 +/- 2.0 years (range 2.5-10.8 years). Six (24.0%) of them had strabismus. The spherical equivalent (SE) refraction for regimens I, II and III were +5.11 +/- 2.04 D, +5.29 +/- 1.89 D and +5.71 +/- 1.90 D, respectively, and were significant different from the manifest SE (+3.95 +/- 2.17 D) (P < 0.001). There was no statistical difference between regimen I and II in children without strabismus (P = 0.258) or aged older than 5 years (P > 0.050). CONCLUSION: In older children, regimen I was as effective as regimen II and can be used to avoid cyclopentolate toxicity.
26
Comparison of Cyclopentolate Versus Tropicamide Cycloplegia in Children
SHERRI M. EGASHIRA, L Kish, J. Daniel Twelker et al. · Optometry and Vision Science · 1993 · 129 citations